Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2021 Photo Supplied
Carmien Tolmie
Dr Carmien Tolmie says being involved in the Global Challenges Research Fund (GCRF) START grant over the past three years has made a very concrete contribution to her career as a young scientist.

Dr Carmien Tolmie – Lecturer in the Department of Microbiology and Biochemistry at the University of the Free State (UFS) – is one of 30 postdoctoral research assistants in the United Kingdom and Africa who have benefited from the £3,7 M Global Challenges Research Fund (GCRF) START grant over the past three years. The grant was made available by the Science and Technology Facilities Council (STFC) in support of the Synchrotron Techniques for African Research and Technology (START) programme. The STFC is based in the United Kingdom.

The grant seeks to build partnerships between world-leading scientists in Africa and the UK who are working on research using synchrotron science. Forming part of this collaboration is the UK’s national synchrotron, Diamond Light Source (Diamond). The synchrotron, one of about 70 in the world, can be explained as a large machine, almost the size of a football field, which accelerates electrons to nearly the speed of light. According to Diamond, these fast-moving electrons produce very bright light, called synchrotron light. Scientists can use this light to study minute matter such as atoms and molecules.

 

Celebrating a new generation of scientists

On 7 June 2021, GCRF START celebrated its successes of the past years via a virtual event, including the new generation of scientists they trained. Diamond Light Source (Diamond) hosted the event.

In a statement issued by Diamond Light Source, Dr Tolmie was said to be one of the rising stars in the newly emerging Structural Biology network in South Africa. The statement reads that Dr Tolmie has made great strides with biocatalysis, investigating enzymes as drug targets for fungal infectious diseases that claim many lives, especially among immunocompromised patients.

Dr Tolmie claims that the workings of the natural world have always interested her, especially how it can be used to sustainably improve human health and agriculture. Observing some of the health challenges in Africa motivated her to take the opportunity to work with Prof Dirk Opperman, Associate Professor in the UFS Department of Microbiology and Biochemistry. Prof Opperman is a GCRF START co-investigator in the UFS Biocatalysis and Structural Biology research group, working on various bacterial and fungal enzymes.

Focusing on structural biology, Dr Tolmie is also working on drug discovery projects to find a sustainable solution through novel antifungal drugs.

To conduct the research that can improve the health of so many people suffering from infectious fungal diseases that can be serious, especially for immunocompromised patients living with HIV/Aids, recipients of organ transplants, patients undergoing chemotherapy and many more, Dr Tolmie will be using the drug discovery method of X-ray crystallographic fragment screening at Diamond Light Source (Diamond). “I was introduced to the concept and power of fragment screening techniques during GCRF START meetings,” says Dr Tolmie.

A research visit to Diamond Light Source in the UK in 2019, where she learned more about the experimental workflow of XChem and the i04-1 beamline, also inspired her to embark on XChem projects for antifungal drug discovery.

 

Exposed to cutting-edge scientific techniques

She attributes her recent appointment as lecturer to the mentoring and training she received through the GCRF START grant, which also funded a secondment to Diamond and the University of Oxford, exposing her to cutting-edge scientific techniques such as XChem fragment screening.

Prof Chris Nicklin, Science Group Leader and Principal Investigator in the GCRF START grant programme, says by providing the new generation of synchrotron users with access to world-class equipment and investing in their skills and capacity, research in the UK and Africa has been enriched and deepened.

“Being involved in the START grant has made a very concrete contribution to my career as a young scientist. GCRF START has also exposed me to many esteemed international scientists and facilities,” says Dr Tolmie.

Specifically alluding to the research that Dr Tolmie is working on, Dr Gwyndaf Evans, START Life Sciences Principal Investigator and principal beamline scientist on Diamond’s VMXm beamline, says: “It has been rewarding to see the relatively modest investment of time and money have such a major impact on the sustainability of research expertise, on the development of careers in Africa, on access to large-scale facilities around the world, and on the nurturing of collaborations and networks in South Africa.”

He continues: “In structural biology, there have been valuable exchanges and collaborations, especially XChem laying the foundations for drug discovery work. START is the beginning of embedding the structural research culture in South Africa and other groups around the world. We look forward to what the future holds.”

Dr Tolmie, who completed her BSc degree in Molecular Biology and Biotechnology at Stellenbosch University, completed her postgraduate studies (BSc Honours degree, MSc, and PhD) at the UFS.

News Archive

Science is diversifying the uses of traditional medicines
2017-07-17

Description: Dr Motlalepula Matsabisa  Tags: traditional medicines, Indigenous Knowledge Systems, Dr Motlalepula Matsabisa, Malaria, priority disease  

Dr Motlalepula Matsabisa.
Photo: Anja Aucamp

According to the World Health Organisation, a large majority of the African population are making use of traditional medicines for health, socio-cultural, and economic purposes. In Africa, up to 80% of the population uses traditional medicines for primary healthcare.

The Indigenous Knowledge Systems (IKS) was identified as a lead programme under the directorship of Dr Motlalepula Matsabisa. Research undertaken by the IKS Lead Programme focuses on some key priority diseases of the country and region – including malaria, HIV, cancer, and diabetes.
 
Not just a plant or tree

Malaria is a priority disease and is prevalent in rural and poor areas, resulting in many traditional health practitioners claiming to treat and cure the disease. There may well be substance to these claims, since as much as 30% of the most effective current prescription medicines are derived from plants.  For instance, chloroquine, artemisinin for malaria, Metformin for diabetes, Vincristine and Vinblastine for cancer, are plant-derived drugs.  

Dr Matsabisa’s current research is investigating a South African medicinal plant that has been shown to have in vitro antiplasmodial activity, with subsequent isolation and characterisation of novel non-symmetrical sesquiterpene lactone compounds offering antimalarial activity. These novel compounds are now patented in South Africa and worldwide. This research is part of the UFS and South Africa’s strive to contribute to the regional and continental malaria problem. The UFS are thus far the only university that has been granted a permit by the Medicines Control Council to undertake research on cannabis and its potential health benefits.

“All of these projects are aimed
at adding value through the scientific
research of medicinal plants, which
can be used for treating illnesses,
diseases, and ailments.”

Recognition well deservedThrough Dr Matsabisa’s research input and contributions to the development of the pharmacology of traditional medicines, he recently became the first recipient of the International Prof Tuhinadrin Sen Award from the International Society of Ethnopharmacology (ISE) and the Society of Ethnopharmacology in India. ISE recognises outstanding contributions by researchers, scientists, and technologists in the area of medicinal plant research and ethnopharmacology internationally.

More recently, Dr Matsabisa undertook research projects funded by the National Research Foundation, as well as the Department of Science and Technology, on cancer, gangrene, and diabetes. He is also involved in a community project to develop indigenous teas with the community. He says, “All of these projects are aimed at adding value through the scientific research of medicinal plants, which can be used for treating illnesses, diseases, and ailments”.

Dr Matsabisa has worked with many local and international scientists on a number of research endeavours. He is grateful to his colleagues from the Department of Pharmacology in the Faculty of Health Sciences, who are dedicated to science research and the research of traditional medicines. The IKS unit also received immense support from the Directorate of Research Development.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept